{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:10:50Z","timestamp":1753891850970,"version":"3.41.2"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA006973, UL1TR003098, S10OD020091"],"award-info":[{"award-number":["P30CA006973, UL1TR003098, S10OD020091"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Acute myeloid leukemia (AML) remains a devastating disease, with low cure rates despite intensive standard chemotherapy regimens. In the past decade, targeted antileukemic drugs have emerged from research efforts. Nevertheless, targeted therapies are often effective for only a subset of patients whose leukemias harbor a distinct mutational or gene expression profile and provide only transient antileukemic responses as monotherapies. We previously presented single agent and combination preclinical data for a novel 3-carbon-linked artemisinin-derived dimer (3C-ART), diphenylphosphate analog 838 (ART838), that indicates a promising approach to treat AML, given its demonstrated synergy with targeted antileukemic drugs and large therapeutic window. We now report new data from our initial evaluation of a structurally distinct class of 2-carbon-linked dimeric artemisinin-derived analogs (2C-ARTs) with prior documented <jats:italic>in vivo<\/jats:italic> antimalarial activity. These 2C-ARTs have antileukemic activity at low (nM) concentrations, have similar cooperativity with other antineoplastic drugs and comparable physicochemical properties to ART838, and provide a viable path to clinical development.<\/jats:p>","DOI":"10.3389\/fonc.2021.790037","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T10:37:41Z","timestamp":1641897461000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["A Novel 2-Carbon-Linked Dimeric Artemisinin With Potent Antileukemic Activity and Favorable Pharmacology"],"prefix":"10.3389","volume":"11","author":[{"given":"Amanda B.","family":"Kagan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blake S.","family":"Moses","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan T.","family":"Mott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganesha","family":"Rai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole M.","family":"Anders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle A.","family":"Rudek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curt I.","family":"Civin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.05.016","article-title":"Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades","volume":"21","author":"Kantarjian","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33458","article-title":"De Novo Acute Myeloid Leukemia: A Population-Based Study of Outcome in the United States Based on the Surveillance, Epidemiology, and End Results (SEER) Database 1980 to 2017","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-019-0774-x","article-title":"Recent Drug Approvals for Acute Myeloid Leukemia","volume":"12","author":"Lai","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients With Acute Myelogenous Leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.3390\/cells9112493","article-title":"Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments","volume":"9","author":"Scholl","year":"2020","journal-title":"Cells"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-021-00619-3","article-title":"IDH Inhibitors in AML-Promise and Pitfalls","volume":"16","author":"McMurry","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S118116","article-title":"Endoperoxide Antimalarials: Development, Structural Diversity and Pharmacodynamic Aspects With Reference to 1,2,4-Trioxane-Based Structural Scaffold","volume":"10","author":"Rudrapal","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e3282f19ec4","article-title":"Artemisinins and Synthetic Trioxolanes in the Treatment of Helminth Infections","volume":"20","author":"Keiser","year":"2007","journal-title":"Curr Opin Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e10370","DOI":"10.1371\/journal.pone.0010370","article-title":"Artemisinin-Derived Dimers Have Greatly Improved Anti-Cytomegalovirus Activity Compared to Artemisinin Monomers","volume":"5","author":"Arav-Boger","year":"2010","journal-title":"PloS One"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e24334","DOI":"10.1371\/journal.pone.0024334","article-title":"An Artemisinin-Derived Dimer has Highly Potent Anti-Cytomegalovirus (CMV) and Anti-Cancer Activities","volume":"6","author":"He","year":"2011","journal-title":"PloS One"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.18.4.767","article-title":"The Anti-Malarial Artesunate Is Also Active Against Cancer","volume":"18","author":"Efferth","year":"2001","journal-title":"Int J Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1124\/mol.64.2.382","article-title":"Molecular Modes of Action of Artesunate in Tumor Cell Lines","volume":"64","author":"Efferth","year":"2003","journal-title":"Mol Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e82962","DOI":"10.1371\/journal.pone.0082962","article-title":"Anticancer Properties of Distinct Antimalarial Drug Classes","volume":"8","author":"Hooft van Huijsduijnen","year":"2013","journal-title":"PloS One"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.055053","article-title":"The Role of Lymphatic Transport on the Systemic Bioavailability of the Bcl-2 Protein Family Inhibitors Navitoclax (ABT-263) and ABT-199","volume":"42","author":"Choo","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/bcmd.2002.0530","article-title":"Genomic Imbalances in Drug-Resistant T-Cell Acute Lymphoblastic CEM Leukemia Cell Lines","volume":"29","author":"Efferth","year":"2002","journal-title":"Blood Cells Mol Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3038-2","article-title":"Evaluation of Artemisinins for the Treatment of Acute Myeloid Leukemia","volume":"77","author":"Drenberg","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6896","article-title":"Artemisinin-Derived Dimer ART-838 Potently Inhibited Human Acute Leukemias, Persisted In Vivo, and Synergized With Antileukemic Drugs","volume":"7","author":"Fox","year":"2016","journal-title":"Oncotarget"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1231","article-title":"Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL(+) B-Lineage Acute Lymphoblastic Leukemia","volume":"23","author":"Budhraja","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1021\/jm400058j","article-title":"Synthesis and Antimalarial Efficacy of Two-Carbon-Linked, Artemisinin-Derived Trioxane Dimers in Combination With Known Antimalarial Drugs","volume":"56","author":"Mott","year":"2013","journal-title":"J Med Chem"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003429","article-title":"Antileukemic Efficacy of a Potent Artemisinin Combined With Sorafenib and Venetoclax","volume":"5","author":"Moses","year":"2021","journal-title":"Blood Adv"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-513044","article-title":"Crenolanib Is Active Against Models of Drug-Resistant FLT3-ITD-Positive Acute Myeloid Leukemia","volume":"122","author":"Zimmerman","year":"2013","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1037","article-title":"In Vitro and In Vivo Clinical Pharmacology of Dimethyl Benzoylphenylurea, A Novel Oral Tubulin-Interactive Agent","volume":"11","author":"Rudek","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/BF01062139","article-title":"Testing for the Equality of Area Under the Curves When Using Destructive Measurement Techniques","volume":"16","author":"Bailer","year":"1988","journal-title":"J Pharmacokinet Biopharm"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600820718","article-title":"Estimation of Variance for AUC in Animal Studies","volume":"82","author":"Yuan","year":"1993","journal-title":"J Pharm Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e693","DOI":"10.1371\/journal.pone.0000693","article-title":"Artesunate Induces ROS-Mediated Apoptosis in Doxorubicin-Resistant T Leukemia Cells","volume":"2","author":"Efferth","year":"2007","journal-title":"PloS One"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-604975","article-title":"Inhibition of Mcl-1 With the Pan-Bcl-2 Family Inhibitor (-)BI97D6 Overcomes ABT-737 Resistance in Acute Myeloid Leukemia","volume":"126","author":"Pan","year":"2015","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-707414","article-title":"Venetoclax Responses of Pediatric ALL Xenografts Reveal Sensitivity of MLL-Rearranged Leukemia","volume":"128","author":"Khaw","year":"2016","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14539","article-title":"FLT3 Activating Mutations Display Differential Sensitivity to Multiple Tyrosine Kinase Inhibitors","volume":"8","author":"Nguyen","year":"2017","journal-title":"Oncotarget"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000919","article-title":"Gilteritinib Is a Clinically Active FLT3 Inhibitor With Broad Activity Against FLT3 Kinase Domain Mutations","volume":"4","author":"Tarver","year":"2020","journal-title":"Blood Adv"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.790037\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T12:48:50Z","timestamp":1642682930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.790037\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,11]]},"references-count":29,"alternative-id":["10.3389\/fonc.2021.790037"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.790037","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2022,1,11]]},"article-number":"790037"}}